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ARTICLE

Commonalities across computational workﬂows for
uncovering explanatory variants in undiagnosed cases
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Stephan Züchner6, Elizabeth Blue7, Hane Lee8,9, Alden Huang8, Lisa Bastarache10, Anna Bican10, Joy Cogan10, Shruti Marwaha11,
Anna Alkelai12, David R. Murdock13, Pengfei Liu13,14, Daniel J. Wegner2, Alexander J. Paul15 and Undiagnosed Diseases Network*,
Shamil R. Sunyaev1,4 and Isaac S. Kohane 1 ✉
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PURPOSE: Genomic sequencing has become an increasingly powerful and relevant tool to be leveraged for the discovery of
genetic aberrations underlying rare, Mendelian conditions. Although the computational tools incorporated into diagnostic
workﬂows for this task are continually evolving and improving, we nevertheless sought to investigate commonalities across
sequencing processing workﬂows to reveal consensus and standard practice tools and highlight exploratory analyses where
technical and theoretical method improvements would be most impactful.
METHODS: We collected details regarding the computational approaches used by a genetic testing laboratory and 11 clinical
research sites in the United States participating in the Undiagnosed Diseases Network via meetings with bioinformaticians, online
survey forms, and analyses of internal protocols.
RESULTS: We found that tools for processing genomic sequencing data can be grouped into four distinct categories. Whereas wellestablished practices exist for initial variant calling and quality control steps, there is substantial divergence across sites in later
stages for variant prioritization and multimodal data integration, demonstrating a diversity of approaches for solving the most
mysterious undiagnosed cases.
CONCLUSION: The largest differences across diagnostic workﬂows suggest that advances in structural variant detection,
noncoding variant interpretation, and integration of additional biomedical data may be especially promising for solving chronically
undiagnosed cases.
Genetics in Medicine (2021) 23:1075–1085; https://doi.org/10.1038/s41436-020-01084-8

INTRODUCTION
Next-generation exome sequencing (ES) and genome sequencing
(GS) have revolutionized the process for diagnosing rare and novel
genetic conditions.1 Traditionally, the diagnostic process has
primarily been driven by phenotype, with clinicians comparing
patients’ symptoms to others encountered in their prior experience
and clinical training and/or to a knowledgebase of known human
diseases.2 In a typical undiagnosed case, however, either a patient’s
phenotype is not indicative of any known disease, or tests to
conﬁrm the presence of a suspected genetic condition are
inconclusive. In these instances, ES and GS have enabled healthcare providers to pursue a genetics-driven diagnostic approach in
parallel, where the genetic variation uncovered in a patient can be
assessed with respect to not only its known phenotypic associations3 but also to its prevalence in background populations,4
predicted pathogenicity,5 functional consequences, and mode of
inheritance to reveal novel disease-causing loci. Indeed, while
traditional clinical case review and directed diagnostic assays
continue to solve difﬁcult cases, ~74% of newly diagnosed genetic
conditions have been attributed to analyses of ES and GS data.6,7
1

However, the diagnosis rate for patients with potentially unique
genetic conditions is still ~35%,7 suggesting ample opportunity for
methodological improvements to advance our understanding of the
genetic underpinnings of phenotypic extremes.
With this goal in mind, cross-institutional initiatives such as
Care4Rare in Canada (http://care4rare.ca) and Solve-RD in Europe
(http://solve-rd.eu) have been established to connect and enable
clinical researchers to uncover the genetic origins of disease in
undiagnosed patients. In addition to furthering basic genetics
research, these efforts have provided scores of patients with an
end to diagnostic uncertainty and access to additional services.8
The most expansive undiagnosed initiative in the United States is
the Undiagnosed Diseases Network (UDN), which encompasses 12
clinical sites and has, since its inception in 2014, cumulatively
diagnosed over 400 individuals and described over 30 novel
syndromes.7 Each UDN clinical site is staffed with specialists who
develop and apply complex suites of bioinformatics tools to
analyze sequencing data and uncover disease-causing variants.9
These sites each underwent a competitive application process and
were selected to join the UDN due to their demonstrated track
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record of diagnosing difﬁcult cases and characterizing novel
genetic conditions through ongoing research efforts. The workﬂows implemented at these sites are thus representative of the
state-of-the-art in rare disease diagnostic efforts.
We gathered details about 12 UDN bioinformatics pipelines,
determined recurrent steps in a typical diagnostic evaluation, and
identiﬁed consensus approaches. Moreover, we highlight substantial differences across pipelines regarding overall organization
and incorporated tools. The comprehensive snapshot of effective
computational workﬂows presented here can direct clinical teams
interested in initiating genomic sequencing usage or re-evaluating
patients who have had inconclusive genetic testing.
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MATERIALS AND METHODS
Participating sites
Sequence analysis pipeline details were collected from the CLIA-certiﬁed
sequencing core at Baylor Genetics (BaylorSeq) and 11 UDN clinical sites:
Baylor College of Medicine (BCM), Duke University and Columbia University
Institute for Genomic Medicine (Duke/Columbia), three Harvard-afﬁliated
hospitals and Brigham Genomic Medicine (Harvard), University of Miami
Miller School of Medicine (Miami), National Institutes of Health (NIH),
University of Washington School of Medicine and Seattle Children’s
Hospital (PaciﬁcNW), Stanford Center for Undiagnosed Diseases (Stanford),
University of California–Los Angeles (UCLA), University of Utah Health
Center for Genetic Discovery (Utah), Vanderbilt University Medical Center
(Vanderbilt), and Washington University School of Medicine (WUSTL). The
University of Pennsylvania and Children’s Hospital of Philadelphia clinical
site had yet to process sequencing data for a UDN case at the time of
writing and thus is excluded from this study.

Data collection
We systematically collected details about each UDN site’s computational
diagnostic workﬂows using a combination of in-person and virtual
meetings with bioinformaticians and genetic counselors, online survey
forms, and inspections of published papers and internal protocols.10–12

RESULTS
Overview of diagnostic workﬂow components
Before applying to the UDN, a patient has typically endured
extensive prior testing by multiple clinicians over the course of a
multiyear “diagnostic odyssey.” As part of the application process,
UDN clinical sites review patients’ health records to assess whether
the UDN evaluation may aid in the identiﬁcation of a diagnosis.
Accepted patients undergo an in-person evaluation at a clinical site
(Fig. 1a). In most cases, blood, saliva, and/or ﬁbroblast samples of
affected and unaffected individuals in the family are collected
during this evaluation or beforehand via mailed-in collection kits.
These samples are sequenced at BaylorSeq; all sequencing data are
made available to the clinical site within weeks (Fig. 1b). Variants in
disease-causing genes related to the clinical phenotype, medically
actionable pathogenic variants in disease-causing genes unrelated
to the clinical phenotype, and heterozygote status for select
recessive Mendelian conditions are listed in a clinical report issued
by BaylorSeq in accordance with the UDN protocol and following
American College of Medical Genetics and Genomics (ACMG) variant
classiﬁcation guidelines.13 At 8 of the 11 clinical sites surveyed,
researchers simultaneously perform local analyses of the sequencing
data in an attempt to identify “strong candidate” variants that may
explain the patient’s symptoms (Fig. 1c, d); three surveyed sites run
their local pipelines only when BaylorSeq’s clinical report is
inconclusive. Once candidate variants are highlighted via clinical
sites’ and BaylorSeq’s analyses, there are three ways by which their
causality is established. First, human and animal databases are
queried for genotype-matched individuals with symptomatic
concordance with the patient.14–17 Second, experiments are
simultaneously performed to evaluate the in vivo effect of candidate

variants in model organisms or cell lines. Third, the presence of
secondary phenotypes indicated by genotype-matched individuals
or in vivo experiments are conﬁrmed in affected patients (Fig. 1e).
Causal variants revealed through these steps are conﬁrmed by
Sanger sequencing, broadly shared by the UDN (Extended Data
Note 1), and ideally lead to a molecular diagnosis for a patient,
which in and of itself represents a turning point in a patient’s
diagnostic odyssey, and also can inform positive therapeutic
changes (Fig. 1f).18
The computational tools used to ﬁnd explanatory genetic
variants change constantly with newly available technologies and
newly encountered disease etiologies. Despite these iterative
improvements to bioinformatics pipelines, the primary roles
that computational tools play in the overall variant prioritization
process can be categorized as follows: (1) aligning sequencing
reads to a reference human genome (Fig. 1g), (2)
identifying genetic variants present in the individual from the
sequencing reads (Fig. 1h), (3) annotating those variants with
relevant information (Fig. 1i), and ﬁnally (4) ﬁltering and
prioritizing variants that are likely to cause the patient’s condition
(Fig. 1j). In the following sections, we delve into the purpose of
and tools used in each of these categories.
Aligning next-generation sequencing reads
Aligning next-generation sequencing reads to a reference human
genome is the necessary ﬁrst step for all sequence analysis pipelines
(Fig. 1g); the ubiquity of this step has resulted in community-driven
standardization.19 Eight sites regularly realign reads after BaylorSeq’s
initial alignment, whereas three sites realign reads only in speciﬁc
circumstances, such as during reanalysis of a patient’s prior
sequencing data. Realignment is necessary for six sites whose
pipelines are conﬁgured for the GRCh37/hg19 human genome
build, as genetic testing laboratories including BaylorSeq now
provide reads aligned to the newer GRCh38/hg38 build. Realignment uses either an open-source implementation of the
Burrows–Wheeler Aligner (BWA-MEM) (used regularly by six sites
and in speciﬁc circumstances, as described above, by two sites) or
Illumina/Edico’s DRAGEN aligner (used regularly by BaylorSeq and
two clinical sites and in speciﬁc circumstances by one clinical site).
Simple variant calling
Calling single-nucleotide variants (SNVs) and short insertions and
deletions (indels) from aligned reads is the next step in sequence
processing (Fig. 1h) and is often accomplished using the Genome
Analysis Toolkit (GATK) best practices workﬂow,20 though Google’s
DeepVariant21 and Real Time Genomics’ PolyBayes implementation (https://www.realtimegenomics.com) perform competitively
for this task and are used in addition to GATK by two clinical sites.
BaylorSeq calls variants using Illumina/Edico’s DRAGEN platform.
Six clinical sites and BaylorSeq “jointly” call variants across samples
as recommended in GATK to rescue low coverage true variants
and accurately model false variants. In practice, variants are jointly
called with (1) members of the same family, (2) other UDN patients
at the same site, and/or (3) healthy patients internal or external to
an institution. The Variant Quality Score Recalibration (VQSR) step
recommended by GATK to identify technical artifacts, however,
may misclassify real rare variants as false positives; this step is
carefully reviewed or omitted in practice.
Structural variant detection
In contrast to calling simple variants, calling structural variants
(SVs) from GS data is a relatively divergent step, indicating
that best practices have yet to be determined. SVs refer to large
(>50 bp) insertions and deletions, duplications and other copynumber variants (CNVs), short tandem repeat (STR) expansions,
translocations where genomic regions have moved within or
Genetics in Medicine (2021) 23:1075 – 1085
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Fig. 1 Representative clinical workﬂow to uncover disease-causing genetic variants in undiagnosed patients. Upon acceptance to the
Undiagnosed Diseases Network (UDN), (a) an affected patient has an in-person clinical evaluation where extensive phenotyping and additional
tests are performed as needed. (b) Before or during the clinical evaluation, samples of relevant affected and unaffected individuals in a family are
sent for genomic sequencing. (c,d) Sequencing data provided by the sequencing center are analyzed in conjunction with other information in a
back-and-forth process between bioinformaticians, clinicians, and genetic counselors to highlight variants that are likely to explain the patient’s
disease. (e) Matches to the strong candidate explanatory variants identiﬁed in (c) are searched for in databases containing human genetic variant
and corresponding symptom information (e.g., Matchmaker Exchange) or in databases containing animal genetic variants and corresponding
phenotype information (e.g., MARRVEL). Strong candidate variants are also introduced into model organisms or cell lines where possible to assess
in vivo phenotypic impact. (f) Once a candidate variant has been conﬁrmed as disease causal, a molecular diagnosis is provided that can
subsequently be used to tailor clinical management and molecular therapeutics. (g–j) Recurring steps in computational workﬂows to process
genomic sequencing data to call, ﬁlter, and prioritize genetic variants that explain the affected individual’s disease symptoms.

across chromosomes, and inversions where a detached stretch of
DNA was reattached in the opposite orientation. Combining the
output from many SV calling tools—each optimized for detecting
complementary types of SVs and often using distinct information
(e.g., read depth, paired-end reads, or split reads)—is necessary for
comprehensive SV detection.22 Existing SV detection tools have
been reviewed in depth;23 here we list the subset of tools that are
actively used by UDN sites (Table 1, Extended Data Table 1). The
most commonly used tool, Manta, has been shown by independent evaluations to have high sensitivity but also a high false
positive rate.24 Future development of SV benchmarking data sets
for assessing the accuracy of SV detection tools will be essential in
directing the current diverse exploration of techniques toward
community-established best practices.
Quality control of called variants
Conﬁrming the quality of sequencing data and variants is critical
to avoid expending downstream analyses on false variants.
CLIA-certiﬁed genetic testing laboratories check the quality of
unaligned and map-aligned sequencing reads prior to variant
calling for all clinical grade sequencing (Extended Data Note 2).
Four UDN clinical sites regularly conﬁrm the quality of sequencing
Genetics in Medicine (2021) 23:1075 – 1085

reads using a combination of FASTQC, FASTP, MultiQC, BEDTools
(to check coverage), and bam.iobio. Other clinical sites begin
quality control (QC) only after read alignment and variant calling.
QC for Mendelian disease diagnosis encompasses three checks:
(1) sequencing reads are high quality, (2) sequenced samples
correspond to the correct individuals and have expected relatedness, and (3) inheritance patterns across families are as expected
(Table 2, Extended Data Table 1). BaylorSeq performs QC for all
clinical genomic sequencing before providing data to UDN clinical
sites. However, when patients provide their own sequencing data
(as opposed to BaylorSeq providing newly acquired data) or when
“research” (as opposed to clinical) sequencing is provided, clinical
sites perform QC. Most sites have nearly identical steps for check 1
and similar QC for checks 2 and 3. In practice, QC has identiﬁed
incorrectly related or labeled samples and poor overall quality of
sequencing reads that were remedied via resequencing before
subsequent analyses.11 Notably, existing QC tools rarely “ﬂag”
anomalous samples; users must accurately interpret results.
Annotation and ﬁltering of genetic variants
Even after removing low quality calls, a single genome can have
several thousand unique genetic variants uncovered. Efﬁcient,
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Table 1.

Structural variant (SV) callers in use at clinical sites.
BaylorSeq

BCM

Duke/
Columbia

Harvard

Miami

NIH

PaciﬁcNW

Stanford

UCLA

Utah

Vanderbilt

WUSTL

■

□

□

□

□

□

□

■

■

□

■

■

■

■

□

□

Find SVs from sequencing reads
Mantaa

■

ExpansionHunter

■

GATKb

■

■
□

□

LUMPY

□

CNVnator

□

■

■
■

■

RUFUS

■

CNVkit
□

BreakDancer
Illumina DRAGEN
depth-based CNV caller

■
■
■

■

■
■

SvABA: SV/indel
Analysis by Assembly

■

CoNIFERc

■

ERDS: estimation by
reads depth w/ SNVs
BreakSeq2

□

DELLY2

□

Jointly call and/or genotype SVs
■

smoove
□

SVTyper

■

■

□

□

Annotate SVs
AnnotSV

■

■

■

■

■

gnomAD-SV

■

■
■

□

duphold

□

Run or combine output from other tools
XHMM

■

■

■

SURVIVOR

□

Parliament2

■

■

■ Tool called directly. □ Tool called indirectly (e.g., by a wrapper).
Each SV calling tool identiﬁes subsets of SVs by type or other factors, and so in practice, the output of multiple methods must typically be combined and
considered together. Wrapper tools that automatically call and combine results from multiple other SV detection methods improve the efﬁciency of this
process. Duke/Columbia, NIH, Stanford, and Vanderbilt only use SV calling tools in speciﬁc cases or contexts rather than as part of their regular
pipelines. Tool citations are listed in Extended Data Table 1.
CNV copy-number variant, SNV single-nucleotide variant.
a
Manta is used by BaylorSeq to generate putative SV calls, which are then shared with the clinical sites.
b
The two functions from GATK used are GermlineCNVCaller and DepthOfCoverage (DoC); the latter is used to detect exonic deletions or duplications.
c
In contrast to other tools, CoNIFER runs on exome sequencing (ES) data rather than genome sequencing (GS) data.

automated annotation and ﬁltering of these variants is the next
step of the variant prioritization process (Fig. 1i, Extended Data
Table 2). Annotations fall into four categories: (1) known disease
associations, (2) prevalence across healthy human populations, (3)
predicted pathogenicity and functional effect, and (4) inheritance.
Many scores exist across the ﬁrst three categories;25 in the
following sections we explore those that are used in practice for
rare disease diagnosis.
Known disease-associated genes
Many speciﬁc genetic variants have previously been determined
to cause human disease, and it is useful to ﬁrst look for the
presence of these variants in a patient’s sequencing data.
Databases compiling disease-causing variants, the genes they
impact, and their phenotypic associations are used by ten clinical
sites (Table 3). Genetic testing laboratories, including BaylorSeq,

use these in addition to internal databases containing similar
information. Disease-relevant variants are listed on clinical reports
and are considered during the initial pass of each UDN case at all
clinical sites.
Variant segregation in healthy human populations
Several positions within the human genome naturally vary across
healthy individuals, and “common” variants at these positions are
unlikely to cause the conditions under investigation by the UDN.
Though rare combinations of otherwise common variants may
lead to disease,26 clinical sites do not currently consider all
common variant combinations. Instead, variants observed more
than 1 in 100 times across healthy populations (i.e., minor allele
frequency [MAF] > 0.01) are typically excluded during the ﬁrst pass
of the data. The exact MAF threshold used depends on the
suspected mode of inheritance. Lower MAF thresholds are used
Genetics in Medicine (2021) 23:1075 – 1085
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Table 2.

Quality control (QC) checks of variants for rare disease diagnosis.

QC checks of variant data fall into three main categories, listed in bold above. Although some tools can be used for many of these steps, we illustrate here
which QC steps they are actually used for in practice. Note the clariﬁcations for some of the QC tools and steps listed in footnotes a–e. Tool citations are
listed in Extended Data Table 1.
ES exome sequencing, GS genome sequencing, SNV single-nucleotide variant.
a
BCFtools refers to the Wellcome Trust Sanger Institute’s suite of tools: BCFtools, VCFtools, SAMtools, and HTSlib.
b
These tools either call de novo variants from sequencing reads to reduce false positive calls or provide de novo frequencies where a high frequency
indicates a likely false positive.
c
The expected transition (Ts) to transversion (Tv) ratios assume variants are called with respect to the human reference sequence; if variants are called with
respect to computed ancestral alleles, the expected Ts/Tv ratio for ES should be ~1.
d
Expected relatedness between family members is estimated using a “kinship coefﬁcient”; unexpectedly low kinship implies a family member is not as
related as was originally assumed, unexpectedly high kinship suggests consanguinity, and maximal kinship implies an accidental sample duplication.
e
Mosaicism—where an individual contains a mix of genetically distinct cells—may be relevant for disease rather than only indicative of sequencing errors.

for suspected dominant conditions because the variants causing
the extremely rare phenotypes of UDN patients are assumed to be
naturally selected against and thus equally rare in the general
population and entirely absent in control population databases.
Higher MAF thresholds are used for suspected recessive conditions because heterozygous individuals would not be expected to
manifest severe disease features.
All UDN sites use data from the Broad Institute’s Genome
Aggregation Database (gnomAD) to compute MAFs, and seven
sites also compute MAFs from smaller or population-speciﬁc data
sets on a case-by-case basis (Table 3). Two sites eliminate variants
that are homozygous in three or more healthy individuals in these
Genetics in Medicine (2021) 23:1075 – 1085

data sets. At the NIH site, rather than thresholding on MAFs
computed directly from variant proportions in gnomAD, 95%
Wilson conﬁdence score intervals computed from these proportions are used to retain rare variants occurring in low coverage
regions. Finally, ﬁve sites ﬂag variants that are present in data sets
internal to their institutions, because variants present in asymptomatic or differently symptomatic individuals are unlikely to be
disease-relevant.
Eight sites consult SV databases to check the existence and/or
MAF of detected SVs (Table 3, Extended Data Table 1). Multiple
databases are checked in practice because the SV detection tools
used across databases differ, so the absence or rarity of an SV in
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● Tool used by default. ⚬ Tool used in speciﬁc cases or contexts only.

b

LoFtool

M-o/e-UF: missense observed/expected upper-bound fraction

s_het: selective effect of heterozygous LoF

Knowledge of variation within human populations with and without disease can be effectively used to assess the likelihood of a variant to cause the genetic condition under investigation. Tool and data set
citations are listed in Extended Data Table 1.
a
Human sequence variation data sets that are internal to particular institutions and used by clinical sites surveyed here include variants present in patients from Baylor College of Medicine (BCM), the Institute
for Genomic Medicine (Duke/Columbia), Brigham Genomic Medicine (Harvard), the NIH Undiagnosed Diseases Program (NIH), Centers for Mendelian Genomics (PaciﬁcNW), University of California–Los
Angeles (UCLA), the Centre d’Etude du Polymorphisme Humain (Utah), and BioVu (Vanderbilt), and a curated set of copy-number variants (CNVs) detected via genome sequencing (GS) and conﬁrmed via
chromosomal microarray analysis (Washington University School of Medicine [WUSTL]).
b
The contexts in which speciﬁc human population variant data sets are used include historical reasons (ExAC), when a variant’s gnomAD-derived MAF is 0 or close to 0 (TOPMed), when patients’ inferred
ancestry is non-European (TOPMed), Middle Eastern (GME), Japanese (xKJPN), Asian (GenomeAsia), and/or Iranian (Iranome), and when a predicted structural variant impacts a clinically relevant gene
(gnomAD-SV, DGV, ClinGen, DECIPHER).

●
MTR: missense tolerance ratio

●
●
LIMBR: Localized Intolerance Model w/ Bayesian Regression

Table 3 continued
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one database may reﬂect a particular SV detection approach
rather than true population rarity.
Simple genetic variation observed across healthy humans tends
to be sparsely distributed with varying degrees of impact. These
features can be used to capture how regions of the human
genome may be intolerant of loss-of-function (LoF) variants, such
as frameshift or protein-truncating variants. Nine surveyed sites
incorporate selective constraint scores derived from and released
with gnomAD data in their diagnostic pipelines, with the
probability of heterozygous LoF intolerance scores and missense
constraint Z scores used most commonly (Table 3).
Predicted pathogenicity and functional effect of variants
Various tools predict the pathogenicity of uncovered variants.25
Values derived from cross-species comparative genomics contribute heavily to pathogenicity predictors, as positions that are
conserved across species tend to be functionally critical. However,
since most candidate coding variants are evolutionarily wellconserved, only ﬁve sites directly consider conservation in their
diagnostic pipelines (Table 4, Extended Data Table 1).
The most commonly used pathogenicity predictors for rare
disease diagnosis—used by eight clinical sites each—are Combined Annotation Dependent Depletion (CADD) and Rare Exome
Variant Ensemble Learner (REVEL), each of which consider multiple
variant annotations and where scores >25 and >0.3 respectively
indicate likely pathogenic variants. Nearly all predicted pathogenicity scores used, with the exception of ReMM, indicate disease
relevance primarily for coding variants.27
Indeed, predicting and experimentally validating the pathogenic impact of noncoding variants is notoriously difﬁcult. All
12 sites use tools to predict how noncoding variants alter
expected gene expression and splicing. Few sites use the same
subset of tools for this task, though SpliceAI is the most commonly
used tool overall (Table 4).
Mode of inheritance
After variants have been quality checked, MAF ﬁltered, and
annotated, Mendelian mode of inheritance is evaluated next by
the clinical sites. Some sites simultaneously consider the
functional impact of variants, where, for instance, intergenic or
perceived synonymous variants are excluded.3 Despite the
ubiquity of this step, each site uses different tools for computing
inheritance patterns.
For a dominantly inherited genetic condition to manifest, only
one defective copy of the relevant gene is required, whereas
recessive disease manifestation requires two defective gene
copies. GS of unrelated or distantly related affected individuals
is desired in suspected dominant cases to ﬁnd rare, shared
variants.
In sporadic cases—caused by a single de novo dominant or two
recessive variants—GS of at least the affected individual and both
unaffected parents is desired. Selecting heterozygous variants in
the affected individual that are absent in both unaffected parents
or homozygous variants in the affected individual that are absent
in at least one parent via straightforward segregation analysis
results in a majority of spurious de novo calls. These false positive
calls stem from inadequate sequence coverage or alignment in
parents from whom variants were in fact inherited and/or
inaccurate modeling of underlying variant frequencies. Four sites
regularly use specialized de novo calling tools or databases to
offset these issues (Table 2). Fixing de novo calling errors requires
analysis of sequencing reads, which many genetic testing centers
do not readily provide.
Occasionally in sporadic and/or recessive cases, the same diseasecausing variant is inherited from both heterozygous parents and can
be easily detected as a homozygous variant. Genomic regions
containing only homozygous variants in an affected individual with
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Unlike other tools, DOMINO provides scores per gene rather than per variant.
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nonconsanguineous parents can also indicate an inherited deletion
from one parent or uniparental isodisomy. These latter phenomena,
revealed as Mendelian violations during the QC process (Table 2),
can manifest in a recessive disease despite only one parent being
heterozygous for the disease-causing variant. Often in undiagnosed
recessive cases, two or more different heterozygous variants, each
either inherited or occurring de novo, can give rise to the disease
phenotype; these variants are referred to as compound heterozygous pairs. The complete set of compound heterozygous variant
pairs in any given case is very large, and so ﬁlters—such as
restricting to rare, LoF, likely pathogenic variants—are applied
beforehand. If too few candidate explanatory variants pass these
ﬁlters, the NIH, WUSTL and Miami sites use internal “second tier”
schemes, such as increasing the allowable MAF threshold, to rescue
additional compound heterozygous pairs.28
Integration of nonsequencing data
Cases with nondiagnostic genetic testing have eventually been
solved by reanalysis approaches that leverage additional data,
such as transcriptome sequencing29,30 (RNA-seq) or “deep
phenotyping,”31,32 to complement ES and GS.
Transcriptome sequencing
RNA-seq is increasingly utilized to (1) conﬁrm suspected expressionor splice-altering variants initially prioritized through genomic
sequencing, and/or (2) highlight genes that are aberrantly expressed
relative to healthy, tissue-matched samples from databases such as
GTEx (https://gtexportal.org/).29,30 BCM, Stanford, and UCLA regularly
use RNA-seq data for variant prioritization, and two other sites are
actively working to incorporate RNA-seq data into their workﬂows as
well (Extended Data Table 3). Vanderbilt uses PrediXcan to correlate
observed phenotypes with imputed, rather than directly measured,
gene expression.33
Structured phenotyping
Deep phenotyping of patients is critical to the overall UDN process
(Fig. 1a) and enables clinicians to focus on genes associated with a
patient’s symptoms or suspected disease. Symptom terms are
standardized via the Human Phenotype Ontology (HPO) and
explicitly annotated for each UDN case during the in-person
evaluation.34 Computational tools can reason over these terms to
generate gene panels that complement manual efforts.35 All
clinical sites have access to genes ranked by PhenoTips, a program
embedded into the UDN data server. Eight clinical sites and
BaylorSeq use additional tools to prioritize genes from patients’
phenotypes (Fig. 1j, Extended Data Table 4).36 Amelie is used by
ﬁve sites to scour the literature for examples of genes causing
patients’ observed phenotypes, a process typically performed
manually using the Monarch Initiative’s gene–phenotype browser.
Exomiser is used by three sites to integrate genotype–phenotype
data and runs in parallel to existing pipelines. Finally, pairwise
associations between genes and HPO terms are downloadable
from the HPO website; the union of genes associated with all
annotated HPO terms per patient can be used directly or
intersected with sets of disease-relevant genes from OMIM and
HGMD. This approach is used by three sites regularly but has been
implemented for various projects at all clinical sites.
Workﬂow management and wrapper tools
The complex workﬂows described here must be well-documented,
customizable per case, and provide results in a timely manner and
intuitive format. Case materials should be accessible by collaborative teams of clinicians, bioinformaticians, and genetic counselors.
In practice, all sites use automated platforms to call, annotate, and
prioritize candidate diagnostic variants (Extended Data Table 5,
Extended Data Table 6). Spreadsheets are the most common tool
Genetics in Medicine (2021) 23:1075 – 1085

used by all sites for storing, sharing, and commenting on variantlevel data. Many sites also use commercial solutions for case
management, which has enabled secure transition of certain
workﬂow components to the cloud.
DISCUSSION
Pinpointing the genetic variants giving rise to ultrarare, undiagnosed diseases is a challenging and pressing problem being
tackled on a case-by-case basis by clinical researchers worldwide.
The computational tools utilized during these investigative efforts
reﬂect relevant community standards but can also diverge across
institutions and even across cases handled by the same
clinical team.
The diverse, exploratory techniques employed by UDN clinical
sites can overcome inherent limitations of clinical case review and
standard sequencing interpretation provided by genetic testing
laboratories—both of which rely on existing disease gene
knowledge—by uncovering novel disease loci. For instance,
when no compelling variants were found in phenotypically
prioritized genes in two patients presenting with muscular and
white matter abnormalities, a genetics-driven UDN pipeline
uncovered diagnostic de novo missense variants in both
individuals in TOMM70, a gene previously unassociated with
disease.37 Similarly, sequencing analyses were able to uncover de
novo, heterozygous variants in nine individuals with neurodevelopmental delay and other multisystem anomalies in CDH2, a
gene previously unassociated with a Mendelian neurodevelopmental condition.38
Indeed, divergent aspects of UDN pipelines reﬂect promising
avenues for case reanalysis and reveal areas where technical
developments would be most impactful. Improving SV detection
speciﬁcity would aid in cases with nondiagnostic microarrays,
gene panels, and GS. Experimentally veriﬁable pathogenicity
predictions for noncoding variants may solve cases with
nondiagnostic ES. Finally, automated integration of additional
data, such as RNA-seq,29,30 long-read sequencing,39 and epigenetic modiﬁcations,40 may also increase the diagnostic rate for
cases with inconclusive GS.
Consensus tools used across sites by multiple clinical research
teams have been convincingly evaluated and are easily
incorporated into existing workﬂows external to their original
development environment. Clinical sites strive to incorporate
better tools—including those developed in-house—as they
emerge over time. Flexible, open-source implementations ease
this process and can ultimately shorten the time to and improve
the rate of diagnosis. Initiatives like the UDN provide an
excellent opportunity to assess and share tools and ideas and
jointly develop methods inspired by the most challenging
undiagnosed cases.
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